Inhibition of cyclooxygenase-2: a new targeted therapy for B-cell lymphoma?

Leuk Res. 2004 Feb;28(2):109-11. doi: 10.1016/s0145-2126(03)00260-1.

Abstract

The purpose of this editorial is to highlight the findings reported herein in the paper by Wun et al. on the connection between expression of the cyclooxygenase-2 (COX-2) enzyme and B-cell lymphoma [Leuk. Res., in press]. We will first briefly review key aspects of the COX-2 enzyme, the newly discovered prostaglandin (PG) synthases and their PG products, and their roles both in inflammation and in the pathogenesis of cancer. Having placed the COX pathway in this context, the discussion will then return to the provocative findings of Wun et al. [Leuk. Res., 28, 2004].

Publication types

  • Comment
  • Editorial
  • Review

MeSH terms

  • Cyclooxygenase 2
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors / pharmacology*
  • Cyclooxygenase Inhibitors / therapeutic use
  • Humans
  • Inflammation / etiology
  • Isoenzymes / antagonists & inhibitors*
  • Isoenzymes / physiology
  • Lymphoma, B-Cell / drug therapy*
  • Lymphoma, B-Cell / etiology
  • Membrane Proteins
  • Prostaglandin-Endoperoxide Synthases / physiology
  • Prostaglandins / physiology

Substances

  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors
  • Isoenzymes
  • Membrane Proteins
  • Prostaglandins
  • Cyclooxygenase 2
  • PTGS2 protein, human
  • Prostaglandin-Endoperoxide Synthases